Bifogade filer
PDF
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sverige, 10.00 CET, 10 February 2022 - BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone injuries, will publish its year end report for 2021, on the 17 February 2022 at 08.00 am CET.
The Company will hold a conference call and an online presentation on the same day at
10.00 am CET. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.
The dial-in numbers for the conference call are:
SE: +46 851999383
UK: +44 3333009270
US: +1 8335268383
The presentation will be webcasted and can be accessed from the following weblink:
https://tv.streamfabriken.com/bonesupport-q4-2021
For more information contact:
BONESUPPORT HOLDING AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT (https://bonesupport.com/en-eu/products/). The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 181 million in 2020. Please visit www.bonesupport.com (https://bonesupport.com/en-eu/)for more information.
BONESUPPORT and CERAMENT are registered trademarks (https://bonesupport.com/en-eu/trademarks/)of BONESUPPORT AB.